Feature

Gemcitabine Intravesical System Shows High Disease-Free Survival Rates in BCG-Unresponsive Papillary-Only NMIBC

Monotherapy with a gemcitabine intravesical system demonstrated high disease-free survival rates in patients with bacillus Calmette-Guérin-unresponsive papillary-only high-risk non–muscle-invasive bla...

Share

The SunRISe-1 trial presents promising results for TAR-200, a gemcitabine intravesical therapy for high-risk non–muscle-invasive bladder cancer (NMIBC) unresponsive to BCG. Conducted by Dr. Siamak Daneshmand and colleagues, the study reported an 85.3% disease-free survival rate at 6 months and 69.2% at 18 months, with minimal adverse events. This offers hope for patients lacking treatment options, highlighting TAR-200's potential to redefine management for this challenging disease. The ongoing SunRISe-5 trial aims to further establish its efficacy against standard therapies.

Original Source(s)

Gemcitabine Intravesical System Shows High Disease-Free Survival Rates in BCG-Unresponsive Papillary-Only NMIBC

Monotherapy with a gemcitabine intravesical system demonstrated high disease-free survival rates in patients with bacillus Calmette-Guérin-unresponsive papillary-only high-risk non–muscle-invasive bla...

  • by Chase Doyle

  • February 25, 2026

  • 7 min

Related Content

Syngene and Johns Hopkins Partner to Advance Early-Stage Drug Discovery

Collaboration anchored in Syngene’s SynVent platform and Connector model to accelerate promising academic research

  • February 25, 2026

  • 2 min
What Cats Can Tell Us About Cancer

Large-scale feline sequencing study highlights diagnostic and therapeutic targets shared with human cancers

  • February 25, 2026

  • 2 min
Making Laparoscopic Cholecystectomy Safer

Laparoscopic cholecystectomy has become the gold standard for gallbladder removal, with more than 750,000 procedures performed annually in the U.S.

  • by

  • February 24, 2026

  • 3 min